Cardiovascular Sciences Research Centre, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
Biomark Med. 2013 Aug;7(4):535-46. doi: 10.2217/bmm.13.78.
Brugada syndrome is an inherited arrhythmia syndrome predisposing to sudden cardiac death. Six years after its initial description as a clinical entity, the first mutations in SCN5A encoding the cardiac sodium channel Nav1.5 were reported. Over 300 mutations in SCN5A have since been described in addition to mutations in genes encoding Nav1.5 auxiliary units, potassium and calcium channels. This review summarizes the current knowledge on the genetics of Brugada syndrome, focusing on SCN5A, and discusses its use as a biomarker for diagnosis, prognosis and treatment.
Brugada 综合征是一种遗传性心律失常综合征,易导致心源性猝死。在最初将其描述为一种临床实体六年后,首次报道了编码心脏钠离子通道 Nav1.5 的 SCN5A 中的突变。此后,除了编码 Nav1.5 辅助单位、钾和钙通道的基因突变外,还描述了 SCN5A 中的 300 多种突变。本综述总结了 Brugada 综合征遗传学的最新知识,重点介绍了 SCN5A,并讨论了其作为诊断、预后和治疗生物标志物的用途。